Mohamed Discusses Newer Chemoimmunotherapy Regimens in Squamous NSCLC
October 31st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Mohamed K. Mohamed, MD, PhD, and participants discussed cemiplimab plus chemotherapy and tremelimumab/durvalumab plus chemotherapy as regimens for a patient with metastatic squamous non–small cell lung cancer.
Using AI to Optimize Therapeutic Choices and QOL in Patients With Cancer
October 26th 2023In an interview with Peers and Perspectives in Oncology, Tim Showalter, MD, MPH, discussed increasing patient quality of life by using artificial intelligence and precision medicine to inform cancer treatment decisions.
Sequencing Choices from First- to Third-Line Regimens in ccRCC
October 25th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Arnab Basu, MD, MPH, asked participants about what sequence of therapies they would use in the first, second, and third lines for a patient with metastatic clear cell renal cell carcinoma. This is the first of 2 articles based on this event.
Where Monoclonal Antibodies and CAR T-cell Therapy Fit in R/R DLBCL
October 25th 2023At a live, virtual event, Farrukh Awan, MD, provided commentary on the current treatment algorithm for patients with relapsed/refractory diffuse large B-cell lymphoma and where the use of the combination regimen tafasitamab and lenalidomide fits in.
Diagnostic Approaches for Hematologic Malignancies With Skin Symptoms
October 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Uma Borate, MBBS, asked physicians about their experiences with patients with hematological malignancies with skin manifestations, and how to diagnose and work up these patients. This is the first of 2 articles based on this event.
Managing Adverse Events in EGFR Exon 20 Insertion–Targeted Therapies for NSCLC
October 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Millie S. Das, MD, and participants discussed considerations for managing toxicities of amivantamab and mobocertinib for patients with EGFR exon 20 insertion–positive non–small cell lung cancer.
Riess Reviews Pivotal Trials for Nonmetastatic Lung Cancer
October 19th 2023During a Targeted Oncology™ Clinical Case Forum event in partnership with the Nevada Oncology Society, Jonathan Riess, MD, MS, summarized the outcomes and impact of the PACIFIC and ADAURA trials in patients with nonmetastatic non–small cell lung cancer.
Considerations for Ordering Biomarker Testing in Endometrial Cancer
October 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Bradley Corr, MD, discussed the importance of mismatch repair deficiency testing and the value of next-generation sequencing in patients with advanced endometrial cancer.
Huppert Discusses Later-Line Therapy Decisions in HR+, HER2– Metastatic Breast Cancer
October 18th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Laura Huppert, MD, and participants discussed treatment approaches for a patient HR-positive, HER2-negative breast cancer with liver and lung metastases who continues to progress on endocrine therapy and CDK4/6 inhibitors.
Arend Discusses Immune Checkpoint Inhibition for Recurrent dMMR Endometrial Cancer
October 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Rebecca Arend, MD, and participants discussed the use of single-agent immune checkpoint inhibitor as opposed to pembrolizumab plus lenvatinib in a patient with recurrent mismatch-repair deficient endometrial cancer.
Discussing Rationale for Combination Therapy in Metastatic Melanoma
October 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hussein A. Tawbi, MD, PhD, and participants discussed which first-line therapy they would recommend for a 78-year-old patient with metastatic melanoma and no BRAF-activating mutation. This is the first of 2 articles based on this event.
Immunotherapy Plus TKI Yields Impressive Results for Subgroups With Advanced RCC
October 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel George, MD, discussed the CheckMate 9ER trial in terms of bone, liver, and lung metastases and other subgroups in patients with advanced clear cell renal cell carcinoma.
Randall Reviews Efficacy and Safety of Niraparib as Primary Maintenance for Ovarian Cancer
October 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Leslie M. Randall, MD, MAS, evaluated the outcomes of the PRIMA/ENGOT-OV26/GOG-3012 study of niraparib as primary maintenance therapy for patients with ovarian cancer.
Targeting BCMA With Teclistamab Produces Impactful Results in RRMM
October 12th 2023In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.
Physicians Discuss Treatment Preference in R/R B-Cell Precursor ALL
October 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Nicholas Short, MD, and participants discussed which patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia they would treat with inotuzumab ozogamicin.
Lunning Discusses Defining and Approaching Treatment for Early-Relapsed DLBCL
October 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Matthew A. Lunning, DO, and participants discussed how they approach treatment for a patient with diffuse large B-cell lymphoma who relapsed 8 months after primary therapy.
Physicians Discuss Elacestrant Vs Alternatives in ER+, HER2- MBC
October 9th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.
Single-Agent Talquetamab Stands Out in Later-Line Treatment of RRMM
October 5th 2023In the second article of a 2-part series, Amrita Krishnan, MD, looks at the overall landscape of treatment for patients with relapsed/refractory multiple myeloma and how the use of single-agent talquetamab stands out in comparison with other treatment options.
Randomized Trial Provides Biomarker and CNS Sotorasib Data in NSCLC
October 4th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the results of the phase 3 CodeBreaK 200 trial in patients with KRAS G12C-positive lung cancer. This is the second article based on this event.